Trust Point’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.15M Buy
75,482
+7,799
+12% +$207K 0.16% 80
2026
Q2
$1.63M Buy
67,683
+35,006
+107% +$916K 0.14% 89
2026
Q1
$918K Buy
32,677
+265
+0.8% +$7.06K 0.08% 133
2025
Q4
$807K Buy
32,412
+1,174
+4% +$29.6K 0.06% 149
2025
Q3
$796K Sell
31,238
-754
-2% -$18.6K 0.06% 149
2025
Q2
$775K Buy
31,992
+7,116
+29% +$166K 0.07% 129
2025
Q1
$630K Sell
24,876
-6,934
-22% -$181K 0.06% 180
2024
Q4
$844K Sell
31,810
-371
-1% -$10.1K 0.06% 188
2024
Q3
$931K Sell
32,181
-2,419
-7% -$70.6K 0.07% 179
2024
Q2
$968K Sell
34,600
-170
-0.5% -$4.68K 0.08% 158
2024
Q1
$965K Sell
34,770
-16,982
-33% -$471K 0.08% 168
2023
Q4
$1.49M Buy
+51,752
New +$1.56M 0.12% 90

Other funds holding PFE

Trust Point's PFE Position: Q3 2026 in Review

Trust Point increased its Pfizer (PFE) stake by 12% in Q3 2026, buying an estimated $207K and bringing the position to 75,482 shares worth $2.15M. The position accounts for 0.16% of the portfolio, ranked #80.

Trust Point first reported a position in PFE in Q4 2023 and has held it in 12 quarters since. 2,556 funds tracked by Wall St. Rank hold PFE as of Q3 2026.

  • Trust Point held 75,482 shares of Pfizer worth $2.15M as of Q3 2026.
  • Trust Point bought 7,799 Pfizer shares in Q3 2026, an estimated $207K.
  • Pfizer made up 0.16% of Trust Point's portfolio in Q3 2026, its #80 holding.
  • Trust Point first reported a position in Pfizer in Q4 2023 and has held it in 12 quarters since.
  • 2,556 funds tracked by Wall St. Rank held Pfizer as of Q3 2026.

Based on Trust Point's 13F filing for Q3 2026, filed 27 Oct 2026.